CO116 Real-World Treatment Patterns, Healthcare Resource Use and Hospital Provider Cost of Recently Approved Treatments for Adult Relapsed or Refractory Acute Lymphoblastic Leukemia in the US: Blinatumomab and/or Inotuzumab Ozogamicin
Abstract
Authors
R. Moon C. Feng N. Rosenthal S. Wade J. David D. Dalton